Section Editors
- Paolo Bruzzi, National Cancer Research Institute
- Carlos Caldas, Cambridge Research Institute
- Ian Cree, Warwick Medical School, Coventry
- Shoukat Dedhar, British Columbia Cancer Agency
- John A Hartley, University College London
- Manami Inoue, National Cancer Center
- Fei-Fei Liu, Princess Margaret Hospital/Ontario Cancer Institute
- Mark McKeage, University of Auckland
- Christophe Nicot, Kansas University Medical Center
- Dirk Vordermark, Martin Luther University Halle-Wittenberg
Executive Editor
- Christna Chap, BioMed Central
Editorial Board | Editorial Team | Instructions for authors | FAQ
Articles
-
BMC Cancer 2012, 12:101Synthetic lethal screen for combination therapy
A novel combination chemotherapy to improve survival rate in patients with neuroblastoma can be identified using a siRNA library-based synthetic lethal screen, suggesting that this approach may help selecting drugs for use in multimodal treatments.
-
BMC Cancer 2012, 12:73BRMS1 as a biomarker for human melanomas
Breast cancer metastasis suppressor 1 (BRMS1) is expressed in the cytoplasm and nucleus of melanocytic cells, and high cytoplasmic expression correlates with increased disease-free survival, indicating that BRMS1 cellular localization might influence melanoma progression.
-
BMC Cancer 2012, 12:36HPV type related to CIN chromosomal aberrations
HPV16-positive high-grade cervical intraepithelial neoplasia (CIN) display fewer chromosomal aberrations than lesions with other HPV types, suggesting that the chromosomal profiles of cervical cancer precursor lesions are related to the HPV type present.
-
BMC Cancer 2011, 11:498A decade of progress in cancer research
To celebrate BMC Cancer's 10th anniversary, we present a special collection of exciting reviews and commentaries that mark key developments in the cancer field over the last decade.
-
BMC Cancer 2011, 11:497Breast cancer type linked to paternal cancer
Patients with lobular breast cancer are more likely to have a father diagnosed with cancer and this association is independent of previous family history of cancer, suggesting that other mechanisms such as sex-specific imprinting might be involved.
- View more articles
Hot topic
BMC Cancer 2012, 12:139 (4 April 2012)
Scope
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
It is journal policy to publish work deemed by peer reviewers to be a coherent and sound addition to scientific knowledge and to put less emphasis on interest levels, provided that the research constitutes a useful contribution to the field.
From the blog
Call for papers
BMC Cancer is accepting submissions to an article series on Cancer bioinformatics: Bioinformatic methods, network biomarkers and precision medicine. Jointly published across BMC Cancer, BMC Bioinformatics, Genome Medicine and Journal of Clinical Bioinformatics, submissions will be welcomed until 1st November 2012. Please see the call for papers for details including how to submit.
Quote
"I strongly believe in the internet and open-access publishing in order to achieve scientific outreach both within academia and outside academia. Open-access allows anyone in the world with access to a computer to access scientific research. These innovative journals are becoming extremely successful and will change the nature of scientific publishing and increase the accessibility of science."
Professor Sally Blower
Semel Institute for Neuroscience & Human Behavior,
UCLA David Geffen School of Medicine, USA
News from the web
Email updates
Receive periodic news and updates relating to BioMed Central.
Indexed by
- CAS
- Embase
- MEDLINE
- PubMed
- Science Citation Index Expanded
- Scopus
RSS
Comments
View more comments